Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. specializes in the innovation and commercialization of advanced drug delivery technologies aimed at enhancing medication safety and efficacy while addressing critical issues like misuse and overdose. Acura Pharmaceuticals is focused on developing unique drug delivery systems. Established in Palatine, US, the company has pivoted to specialize in technologies designed to combat prescription medication misuse.

The company has received funding through 6 deals, with the latest being a Venture Debt round amounting to USD 0. 60 mn on July 10, 2007, backed by Care Capital, Essex Woodlands, and Galen Partners. Acura Pharmaceuticals, Inc. specializes in the research, development, and commercialization of advanced drug delivery technologies aimed at enhancing the safety of medications.

The company's core product offerings include three proprietary technologies: LIMITX™, AVERSION®, and IMPEDE®. LIMITX™ Technology reduces overdose risks by controlling the release of active ingredients. AVERSION® Technology targets opioid abuse through specific gelling agents and irritants in tablets, discouraging misuse. IMPEDE® Technology aims to prevent pseudoephedrine extraction for methamphetamine production.

Acura's products are primarily aimed at pharmaceutical companies and healthcare providers, distributed across the US and other regulated regions. In the most recent year, Acura Pharmaceuticals reported revenue of USD 1,563,000 with an EBITDA of USD -1,124,000. The company generates revenue through its drug delivery systems, partnering with pharmaceutical companies to integrate their technologies into products aimed at reducing medication abuse and misuse. Their revenue model includes licensing agreements and co-development arrangements with major pharmaceutical manufacturers.

Acura Pharmaceuticals plans to utilize the recent funding from July 2007 to support the development and commercialization of new products that enhance drug delivery systems. The company is also evaluating potential expansion into additional markets beyond the US, focusing on regions where prescription medications are stringently regulated. This growth strategy aligns with their ongoing efforts to mitigate public health challenges associated with medication misuse.